Terbium-161 PSMA therapy in mCRPC patient based on an optimized radiolabeling protocol

Sezgin C., UYGUR E., PARLAK Y., Karatay B., Barutca S., Dirican A., ...Daha Fazla

Journal of Radioanalytical and Nuclear Chemistry, 2025 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1007/s10967-025-10352-3
  • Dergi Adı: Journal of Radioanalytical and Nuclear Chemistry
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, Analytical Abstracts, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, Chimica, Communication Abstracts, Food Science & Technology Abstracts, INSPEC, Metadex, Pollution Abstracts, Public Affairs Index, Veterinary Science Database, Civil Engineering Abstracts
  • Anahtar Kelimeler: Prostate-specific membrane antigen, Targeted radionuclide therapy, Terbium-161
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

This study presents a novel radiolabeling technique for [161Tb]-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). The research focused on assessing the radiochemical yield, in vivo stability, and pharmacokinetics of [116 Tb]-PSMA-617 in a clinical setting. Using a sodium acetate buffer and ascorbic acid, a high radiochemical yield (97.98% ± 2.01) was achieved, ensuring stability and purity. The therapy was evaluated to a 77-year-old mCRPC patient resistant to [177Lu]-PSMA-617, showing favorable biodistribution and urinary excretion. Despite initial stability, disease progression occurred, with a TP53 mutation identified via liquid biopsy. While the method holds promise for targeted radionuclide therapy, resistance mechanisms remain a challenge, necessitating further research for optimized patient selection and treatment strategies.